For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

That test could help identify patients at greatest risk for potentially deadly cardiac problems such as coronary artery disease, atrial fibrillation (irregular heartbeat) and heart failure, and ...

Ohio Valley Health Center has reached a significant milestone with the successful completion of its first echocardiogram.This non-invasive ultrasound test, whic ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

A study has revealed that dementia cases in the US are projected to double by 2060, with approximately one million new diagnoses annually.

Other signs, such as sudden confusion, vision changes, or severe headaches, should also never be ignored. By being prepared ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...